Drug Type Biosimilar, Monoclonal antibody |
Synonyms Adalimumab Biosimilar (ODDIFACT SAS), 阿达木单抗生物类似药(ODDIFACT SAS), ADA2401 + [1] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Heart Diseases | Preclinical | France | 01 Jul 2025 | |
| Rheumatic Diseases | Preclinical | France | 01 Jul 2025 | |
| Takayasu Arteritis | Preclinical | United States | 13 Mar 2025 |






